About ALK-Abello
ALK-Abello is a company based in Hørsholm (Denmark) founded in 1923. The company has 2,750 employees as of December 31, 2024. ALK-Abello has completed 2 acquisitions, including Bio-Medical Services and Crystal Laboratory. ALK-Abello offers products and services including Allergy Vaccines, Diagnostics, and Consumer Healthcare. ALK-Abello operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Dren Bio and Vividion Therapeutics, among others.
- Headquarter Hørsholm, Denmark
- Employees 2750 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Alk-Abello A/S Class B
-
Annual Revenue
$771.74 M (USD)14.78as on Dec 31, 2024
-
Net Profit
$113.53 M (USD)67.7as on Dec 31, 2024
-
EBITDA
$189.45 M (USD)49.61as on Dec 31, 2024
-
Latest Funding Round
$110.72 M (USD), Post-IPO
Dec 08, 2017
- Investors
-
Employee Count
2750
as on Dec 31, 2024
-
Investments & Acquisitions
Bio-Medical Services
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of ALK-Abello
ALK-Abello is a publicly listed company on the OMXCOP with ticker symbol ALK_B in Denmark, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of ALK-Abello
ALK-Abello offers a comprehensive portfolio of products and services, including Allergy Vaccines, Diagnostics, and Consumer Healthcare.
Vaccines for treating allergies like pollen and dust mites.
Tools for diagnosing various types of allergies.
Products for managing everyday allergy symptoms.
People of ALK-Abello
Unlock access to complete
Unlock access to complete
Funding Insights of ALK-Abello
Investors in ALK-Abello
ALK-Abello has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Merck.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Pharmaceutical products are manufactured and marketed worldwide.
|
Locked | Locked | Locked |
Investor details for ALK-Abello
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ALK-Abello
ALK-Abello has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Bio-Medical Services and Crystal Laboratory.
Investment portfolio details for ALK-Abello
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Veterinary health products are provided by Bio-Medical Services.
|
Locked | Locked | 1999 | Locked | |
|
Manufacturer of allergy medicines
|
Locked | Locked | 1968 | Locked |
Complete acquisition details for ALK-Abello
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - ALK-Abello
Detailed financials for ALK-Abello
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Alk-Abello Comparisons
Peer comparison for ALK-Abello
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ALK-Abello
ALK-Abello operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Dren Bio and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Therapeutic antibodies are developed for cancer, autoimmune, and serious diseases.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
RNA-editing technologies are provided for precision medicine applications.
|
Detailed competitors of ALK-Abello
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Alk-Abello
Complete news archive for ALK-Abello
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ALK-Abello
ALK-Abello was founded in 1923 and raised its 1st funding round 84 years after it was founded.
ALK-Abello is headquartered in Hørsholm, Denmark.
Carsten Hellmann is the current CEO of ALK-Abello.
As of Dec 31, 2024, the latest employee count at ALK-Abello is 2,750.
Annual revenue of ALK-Abello is $771.74M as on Dec 31, 2024.
ALK is a Danish, Public Biopharma company developing allergy immunotherapies including injections (emergency) and sublingual tablets. As on Nov 2016, they are in Phase III trials for sublingual allergy tablets for house dust mite, Japanese cedar and tree pollen. They have already marketed sublingual tablets for grass and ragweed. They also manufacture adrenaline auto-injections for anaphylaxis.
ALK-Abello's top competitors include Sutro Biopharma, Avidity Biosciences and Antheia.
ALK-Abello offers Allergy Vaccines, Diagnostics, and Consumer Healthcare.
Yes, ALK-Abello is publicly traded on OMXCOP under the ticker symbol ALK_B.
ALK-Abello has made 2 acquisitions, including Bio-Medical Services, and Crystal Laboratory.
ALK-Abello has 1 investor. Key investors include Merck.
The ticker symbol of ALK-Abello is ALK_B on OMXCOP.